Lawsuit Overview
<p>The complaint alleges that during the Class Period defendants violated the federal securities laws by issuing a series of materially false and misleading statements to the market about the Company and by failing to disclose material information about the Company’s plan to merge with Genzyme and that when the market learned the truth, the price of Bioenvision securities increa...
You must register (for free) or login to view the entire case.